{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:27Z","timestamp":1792784967978,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Genenta Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04419-1","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:03:29Z","timestamp":1780304609000},"page":"2216-2226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor-targeted interferon-\u03b1 gene therapy for glioblastoma: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-4718","authenticated-orcid":false,"given":"Bernhard","family":"Gentner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Eoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Barcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Capotondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mazzoleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Francavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Garramone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-4839","authenticated-orcid":false,"given":"Matteo G.","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ferla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Alvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Coltella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-6067","authenticated-orcid":false,"given":"Eugenio","family":"Montini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Hadadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Capt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cuccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Meco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico G.","family":"Legnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ferroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-3924","authenticated-orcid":false,"given":"Francesco","family":"Acerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quintino Giorgio","family":"D\u2019Alessandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Patan\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amleto","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Berno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5662-8978","authenticated-orcid":false,"given":"Pietro Luigi","family":"Poliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-4040","authenticated-orcid":false,"given":"Gaetano","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-527X","authenticated-orcid":false,"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"4419_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta, L. & Pollard, J. W. A timeline of tumour-associated macrophage biology. Nat. Rev. Cancer 23, 238\u2013257 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"4419_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627\u20131651 (2023).","journal-title":"Cell"},{"key":"4419_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4419_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D. & Morton, J. P. Therapeutic targeting of tumour myeloid cells. Nat. Rev. Cancer. 23, 216\u2013237 (2023).","journal-title":"Nat. Rev. Cancer."},{"key":"4419_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171\u20131182 (2025).","journal-title":"Nat. Med."},{"key":"4419_CR6","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas, C., Gill, S. & Klichinsky, M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front. Immunol. 12, 783305 (2021).","journal-title":"Front. Immunol."},{"key":"4419_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","volume":"385","author":"Gentner","year":"2021","unstructured":"Gentner et al. Hematopoietic stem-and progenitor-cell gene therapy for Hurler syndrome. N. Engl. J. Med. 385, 1929\u20131940 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4419_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41591-022-01691-9","volume":"28","author":"KA Sailor","year":"2022","unstructured":"Sailor, K. A. et al. Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain. Nat. Med. 28, 517\u2013527 (2022).","journal-title":"Nat. Med."},{"key":"4419_CR9","doi-asserted-by":"publisher","first-page":"eaaw7843","DOI":"10.1126\/scitranslmed.aaw7843","volume":"12","author":"L Akkari","year":"2020","unstructured":"Akkari, L. et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci. Transl. Med. 12, eaaw7843 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"4419_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578\u2013584 (2021).","journal-title":"Nature"},{"key":"4419_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","volume":"13","author":"F Tucci","year":"2022","unstructured":"Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G. & Aiuti, A. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat. Commun. 13, 1315 (2022).","journal-title":"Nat. Commun."},{"key":"4419_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli, F. et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet 399, 372\u2013383 (2022).","journal-title":"Lancet"},{"key":"4419_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"4419_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/neuonc\/noz185","volume":"22","author":"J De Groot","year":"2020","unstructured":"De Groot, J. et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro. Oncol. 22, 539\u2013549 (2020).","journal-title":"Neuro. Oncol."},{"key":"4419_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol"},{"key":"4419_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","volume":"8","author":"M De Palma","year":"2005","unstructured":"De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211\u2013226 (2005).","journal-title":"Cancer Cell"},{"key":"4419_CR18","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1182\/blood-2006-10-053504","volume":"109","author":"MA Venneri","year":"2007","unstructured":"Venneri, M. A. et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109, 5276\u20135285 (2007).","journal-title":"Blood"},{"key":"4419_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","volume":"19","author":"R Mazzieri","year":"2011","unstructured":"Mazzieri, R. et al. Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512\u2013526 (2011).","journal-title":"Cancer Cell"},{"key":"4419_CR20","doi-asserted-by":"publisher","first-page":"58ra84","DOI":"10.1126\/scitranslmed.3001522","volume":"2","author":"B Gentner","year":"2010","unstructured":"Gentner, B. et al. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med. 2, 58ra84 (2010).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/scitranslmed.3006353","volume":"6","author":"G Escobar","year":"2014","unstructured":"Escobar, G. et al. Genetic engineering of hematopoiesis for targeted IFN-\u03b1 delivery inhibits breast cancer progression. Sci. Transl. Med. 6, 217\u20133 (2014).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","volume":"14","author":"M De Palma","year":"2008","unstructured":"De Palma, M. et al. Tumor-targeted interferon-\u03b1 delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14, 299\u2013311 (2008).","journal-title":"Cancer Cell"},{"key":"4419_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.15252\/emmm.201505395","volume":"8","author":"M Catarinella","year":"2016","unstructured":"Catarinella, M. et al. IFN \u03b1 gene\/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Mol. Med. 8, 155\u2013170 (2016).","journal-title":"EMBO Mol. Med."},{"key":"4419_CR24","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1038\/s41467-018-05315-0","volume":"9","author":"G Escobar","year":"2018","unstructured":"Escobar, G. et al. Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. Nat. Commun. 9, 2896 (2018).","journal-title":"Nat. Commun."},{"key":"4419_CR25","doi-asserted-by":"publisher","first-page":"eabl4106","DOI":"10.1126\/scitranslmed.abl4106","volume":"14","author":"F Birocchi","year":"2022","unstructured":"Birocchi, F. et al. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci. Transl. Med. 14, eabl4106\u2013eabl4106 (2022).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR26","doi-asserted-by":"publisher","first-page":"eado9511","DOI":"10.1126\/scitranslmed.ado9511","volume":"17","author":"F Rossari","year":"2025","unstructured":"Rossari, F. et al. A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice. Sci. Transl. Med. 17, eado9511 (2025).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa, M. et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet 388, 476\u2013487 (2016).","journal-title":"Lancet"},{"key":"4419_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"4419_CR29","first-page":"vdaa082","volume":"2","author":"I Alnahhas","year":"2020","unstructured":"Alnahhas, I. et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol. Adv. 2, vdaa082 (2020).","journal-title":"Neurooncol. Adv."},{"key":"4419_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro. Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro. Oncol."},{"key":"4419_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2023.04.021","volume":"188","author":"A Alafandi","year":"2023","unstructured":"Alafandi, A. et al. Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status. Eur. J. Cancer 188, 122\u2013130 (2023).","journal-title":"Eur. J. Cancer"},{"key":"4419_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11060-020-03505-9","volume":"148","author":"A Natsume","year":"2020","unstructured":"Natsume, A. et al. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. J. Neurooncol. 148, 17\u201327 (2020).","journal-title":"J. Neurooncol."},{"key":"4419_CR33","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood.2024026124","volume":"145","author":"DT Vogl","year":"2025","unstructured":"Vogl, D. T. et al. Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. Blood 145, 944\u2013955 (2025).","journal-title":"Blood"},{"key":"4419_CR34","doi-asserted-by":"publisher","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca, E. A. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 (2021).","journal-title":"Lancet Oncol."},{"key":"4419_CR36","doi-asserted-by":"publisher","first-page":"e163452","DOI":"10.1172\/JCI163452","volume":"134","author":"JT Low","year":"2024","unstructured":"Low, J. T. Understanding and therapeutically exploiting cGAS\/STING signaling in glioblastoma. J. Clin. Invest. 134, e163452 (2024).","journal-title":"J. Clin. Invest."},{"key":"4419_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","volume":"16","author":"Y Zhai","year":"2021","unstructured":"Zhai, Y. et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat. Nanotechnol. 16, 1271\u20131280 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"4419_CR38","doi-asserted-by":"publisher","first-page":"e149258","DOI":"10.1172\/JCI149258","volume":"132","author":"D Chen","year":"2022","unstructured":"Chen, D. et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J. Clin. Invest. 132, e149258 (2022).","journal-title":"J. Clin. Invest."},{"key":"4419_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/neuonc\/noac239","volume":"25","author":"H Awada","year":"2023","unstructured":"Awada, H., Paris, F. & Pecqueur, C. Exploiting radiation immunostimulatory effects to improve glioblastoma outcome. Neuro. Oncol. 25, 433\u2013446 (2023).","journal-title":"Neuro. Oncol."},{"key":"4419_CR40","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri, F. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat. Med. 29, 1370\u20131378 (2023).","journal-title":"Nat. Med."},{"key":"4419_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623, 157\u2013166 (2023).","journal-title":"Nature"},{"key":"4419_CR42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554 (2016).","journal-title":"Cell"},{"key":"4419_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373\u2013380 (2022).","journal-title":"Nature"},{"key":"4419_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2020.06.009","volume":"53","author":"J Wu","year":"2020","unstructured":"Wu, J., Dobbs, N., Yang, K. & Yan, N. Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 53, 115\u2013126 (2020).","journal-title":"Immunity"},{"key":"4419_CR45","doi-asserted-by":"publisher","first-page":"e20221721","DOI":"10.1084\/jem.20221721","volume":"221","author":"JJ Hodgins","year":"2024","unstructured":"Hodgins, J. J. et al. PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway. J. Exp. Med. 221, e20221721 (2024).","journal-title":"J. Exp. Med."},{"key":"4419_CR46","doi-asserted-by":"publisher","first-page":"1384249","DOI":"10.3389\/fimmu.2024.1384249","volume":"15","author":"L Feldman","year":"2024","unstructured":"Feldman, L. et al. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments. Front. Immunol. 15, 1384249 (2024).","journal-title":"Front. Immunol."},{"key":"4419_CR47","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","volume":"14","author":"AZ Wang","year":"2024","unstructured":"Wang, A. Z. et al. Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population. Cancer Discov. 14, 1106\u20131131 (2024).","journal-title":"Cancer Discov."},{"key":"4419_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"4419_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"4419_CR50","doi-asserted-by":"publisher","first-page":"eadp2660","DOI":"10.1126\/scitranslmed.adp2660","volume":"16","author":"JD Bernstock","year":"2024","unstructured":"Bernstock, J. D., Gerstl, J. V. E., Vald\u00e9s, P. A., Friedman, G. K. & Chiocca, E. A. Next-generation CAR T cell therapies for glioblastoma. Sci. Transl. Med. 16, eadp2660 (2024).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"4419_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11060-024-04909-7","volume":"171","author":"EP Grewal","year":"2024","unstructured":"Grewal, E. P. et al. Clinical progress in the development of CAR T cells to treat malignant glioma. J. Neurooncol. 171, 571\u2013579 (2024).","journal-title":"J. Neurooncol."},{"key":"4419_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","volume":"8","author":"E Zonari","year":"2017","unstructured":"Zonari, E. et al. Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. Stem Cell Rep. 8, 977\u2013990 (2017).","journal-title":"Stem Cell Rep."},{"key":"4419_CR54","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.stem.2018.10.008","volume":"23","author":"C Petrillo","year":"2018","unstructured":"Petrillo, C. et al. Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells. Cell Stem Cell 23, 820\u2013832.e9 (2018).","journal-title":"Cell Stem Cell"},{"key":"4419_CR55","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","volume":"3","author":"Y Nishiga","year":"2022","unstructured":"Nishiga, Y. et al. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat. Cancer 3, 1351\u20131366 (2022).","journal-title":"Nat. Cancer"},{"key":"4419_CR56","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/jitc-2020-001202","volume":"8","author":"JL Gardell","year":"2020","unstructured":"Gardell, J. L. et al. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. J. Immunother. Cancer 8, e001202 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4419_CR57","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"4419_CR58","doi-asserted-by":"publisher","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Intracavity generation of glioma stem cell\u2013specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14, eabn1128 (2022).","journal-title":"Sci. Transl. Med."},{"key":"4419_CR59","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/TP.0000000000002840","volume":"103","author":"A Czechowicz","year":"2019","unstructured":"Czechowicz, A., Palchaudhuri, R. & Scheck, A. Selective hematopoietic stem cell ablation using CD117-antibody-drugconjugates enables safe and effective transplantation with immunity preservation. Transplantation 103, 1526 (2019).","journal-title":"Transplantation"},{"key":"4419_CR60","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","volume":"185","author":"A Omer-Javed","year":"2022","unstructured":"Omer-Javed, A. et al. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell 185, 2248\u20132264 (2022).","journal-title":"Cell"},{"key":"4419_CR61","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41467-024-47866-5","volume":"10","author":"D Cesana","year":"2024","unstructured":"Cesana, D. et al. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID. Nat. Commun. 10, 3662 (2024).","journal-title":"Nat. Commun."},{"key":"4419_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1937-9","volume":"18","author":"G Spinozzi","year":"2017","unstructured":"Spinozzi, G. et al. VISPA2: A scalable pipeline for high-throughput identification and annotation of vector integration sites. BMC Bioinformatics 18, 520 (2017).","journal-title":"BMC Bioinformatics"},{"key":"4419_CR63","doi-asserted-by":"publisher","first-page":"bbac551","DOI":"10.1093\/bib\/bbac551","volume":"24","author":"G Pais","year":"2022","unstructured":"Pais, G. et al. ISAnalytics enables longitudinal and high-throughput clonal tracking studies in hematopoietic stem cell gene therapy applications. Brief. Bioinform. 24, bbac551 (2022).","journal-title":"Brief. Bioinform."},{"key":"4419_CR64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/bioinformatics\/bts004","volume":"28","author":"CC Berry","year":"2012","unstructured":"Berry, C. C. et al. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 28, 755\u2013762 (2012).","journal-title":"Bioinformatics"},{"key":"4419_CR65","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","volume":"117","author":"A Biffi","year":"2011","unstructured":"Biffi, A. et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332\u20135339 (2011).","journal-title":"Blood"},{"key":"4419_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02845-y","author":"F Pagani","year":"2025","unstructured":"Pagani, F. et al. Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-025-02845-y (2025).","journal-title":"Acta Neuropathol."},{"key":"4419_CR67","doi-asserted-by":"publisher","unstructured":"Ruiz-Moreno, C. et al. Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.08.27.505439 (2022).","DOI":"10.1101\/2022.08.27.505439"},{"key":"4419_CR68","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281\u20131298 (2021).","journal-title":"Cell"},{"key":"4419_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","volume":"640","author":"TE Miller","year":"2025","unstructured":"Miller, T. E. et al. Programs, origins and immunomodulatory functions of myeloid cells in glioma. Nature 640, 1072\u20131082 (2025).","journal-title":"Nature"},{"key":"4419_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee, A. H. et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat. Commun. 12, 6938 (2021).","journal-title":"Nat. Commun."},{"key":"4419_CR71","doi-asserted-by":"publisher","unstructured":"Browaeys, R. NicheNet-v2: final networks and ligand-target matrices. Zenodo https:\/\/doi.org\/10.5281\/zenodo.7074290 (2022).","DOI":"10.5281\/zenodo.7074290"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04419-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:47Z","timestamp":1781791427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4419"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04419-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.G. and L.N. are cofounders and shareholders of Genenta Science, and received consultancy fees at the time of manuscript preparation. A.C., S.M., V. Brambilla, A. Francavilla and C.R. were employees of Genenta Science at the time of manuscript preparation. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}